TABLE 2.
Total UFH dose per hemodialysis session according to patient characteristics.
| Total UFH dose (IU/kg/session) | p-value1 | ||
| Gender | Male | 126 ± 52 | 0.7 |
| Female | 131 ± 67 | ||
| Diabetes mellitus | Yes | 130 ± 51 | 0.8 |
| No | 127 ± 64 | ||
| CRP | ≤5 mg/L | 126 ± 58 | 0.8 |
| >5 mg/L | 129 ± 59 | ||
| Albumin | <35 g/dl | 136 ± 68 | 0.5 |
| ≥35 g/dl | 126 ± 56 | ||
| Hemoglobin | Lowest tertile | 125 ± 43 | 0.96 |
| Middle tertile | 129 ± 62 | ||
| Highest tertile | 130 ± 66 | ||
| Antiplatelet therapy | Yes | 129 ± 59 | 0.8 |
| No | 126 ± 58 | ||
| Anticoagulant therapy | Yes | 137 ± 75 | 0.5 |
| No | 127 ± 55 | ||
| History of vascular access dysfunction | |||
| AVF/AVG | Yes (n = 5) | 67 ± 13 | 0.1 |
| No (n = 38) | 92 ± 33 | ||
| Catheter | Yes (n = 27) | 173 ± 55 | 0.055 |
| No (n = 29) | 145 ± 55 | ||
Total UFH dose expressed in IU/kg/session is depicted as mean ± SD.
CRP, c-reactive protein; AVF/AVG, arteriovenous fistula/arteriovenous graft.
1Hypothesis testing of the difference between the different categories of the variable using unpaired t-test (gender, diabetes mellitus, CRP, serum albumin, antiplatelet therapy, anticoagulant therapy, and history of vascular access dysfunction) or one-way anova (hemoglobin tertiles).